• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances: NEPTUNE Clinical Guidance

Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances: NEPTUNE Clinical Guidance

9781009182133
377.94 zł
340.14 zł Save 37.80 zł Tax included
Lowest price within 30 days before promotion: 340.14 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
There are global concerns about the proliferation and misuse of club drugs and novel psychoactive substances, yet we know little about their harms and research on clinical management and treatment remains limited. This book fills the knowledge gap by providing a detailed overview of the research evidence available to date. The book provides a framework that allows readers to understand this large number of new drugs, using classifications based on primary psychoactive effect. Within this framework, the book provides detailed reviews of the more commonly used drugs. Each chapter explores pharmacology, patterns and mode of use, acute and chronic harms, and clinical interventions supported by research evidence. An invaluable resource for clinical staff, this book will support clinicians working in the emergency department, substance misuse and addiction services, mental health services, primary care, sexual health services and more. It will also be of interest to academics and those developing drug policy.
Product Details
97904
9781009182133
9781009182133

Data sheet

Publication date
2022
Issue number
1
Cover
paperback
Pages count
384
Dimensions (mm)
187.00 x 245.00
Weight (g)
680
  • 1. An Introduction to Club Drugs and Novel psychoactive substances; 2. Psychosocial interventions for club drugs and novel psychoactive substances; 3. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) Drug group:: depressants; 4. New Benzodiazepine (BZD) NPS; 5. Synthetic Opioids NPS (fentanyl and non-fentanyl NPS); 6. Ketamine and other NPS with dissociative effects; 7. Nitrous oxide (N2O); 8. Stimulant Club Drugs and novel psychoactive substances; 9. Ecstasy- MDMA, 3,4-methylenedioxymethamphetamine), MDMA analogues and drugs with similar effects; 10 . Methamphetamine; 11. Synthetic cathinones; 12. Hallucinogenic drugs; 13. Synthetic cannabinoid receptor agonists (SCRA).
Comments (0)